{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:34:31Z","timestamp":1765294471553},"publisher-location":"Totowa, NJ","reference-count":13,"publisher":"Humana Press","isbn-type":[{"type":"print","value":"9781617790737"},{"type":"electronic","value":"9781617790744"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-1-61779-074-4_7","type":"book-chapter","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T06:53:40Z","timestamp":1300776820000},"page":"89-98","source":"Crossref","is-referenced-by-count":4,"title":["Cytogenetics of Myeloproliferative Neoplasms"],"prefix":"10.1007","author":[{"given":"Lynda J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,7]]},"reference":[{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","key":"7_CR1_7","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008."},{"key":"7_CR2_7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937\u201351.","journal-title":"Blood"},{"key":"7_CR3_7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.humpath.2008.02.004","volume":"39","author":"CA Smith","year":"2008","unstructured":"Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Human Pathology 2008;39:795\u2013810.","journal-title":"Human Pathology"},{"key":"7_CR4_7","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/leu.2008.218","volume":"22","author":"JT Reilly","year":"2008","unstructured":"Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR\u2013ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008;22:1818\u201327.","journal-title":"Leukemia"},{"key":"7_CR5_7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22:1299\u2013307.","journal-title":"Leukemia"},{"key":"7_CR6_7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2141.2007.06910.x","volume":"140","author":"C Kelaidi","year":"2008","unstructured":"Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. British Journal of Haematology 2008;140:267\u201378.","journal-title":"British Journal of Haematology"},{"key":"7_CR7_7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","volume":"83","author":"N Gangat","year":"2009","unstructured":"Gangat N, Tefferi A, Thanarajasingam G, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. European Journal of Haematology 2009;83:17\u201321.","journal-title":"European Journal of Haematology"},{"key":"7_CR8_7","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009;113:4171\u20138.","journal-title":"Blood"},{"key":"7_CR9_7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","volume":"82","author":"K Hussein","year":"2009","unstructured":"Hussein K, Dyke DLV, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. European Journal of Haematology 2009;82:329\u201338.","journal-title":"European Journal of Haematology"},{"key":"7_CR10_7","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","volume":"88","author":"F Pane","year":"1996","unstructured":"Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction). Blood 1996;88:2410\u20134.","journal-title":"Blood"},{"key":"7_CR11_7","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","volume":"103","author":"J Gotlib","year":"2004","unstructured":"Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1\u2013PDGFR{alpha} fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879\u201391.","journal-title":"Blood"},{"key":"7_CR12_7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/gcc.20629","volume":"48","author":"C Walz","year":"2009","unstructured":"Walz C, Haferlach C, H\u00e4nel A, et al. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes, Chromosomes and Cancer 2009;48:179\u201383.","journal-title":"Genes, Chromosomes and Cancer"},{"key":"7_CR13_7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/leu.2009.79","volume":"23","author":"G Soler","year":"2009","unstructured":"Soler G, Nusbaum S, Varet B, et al. LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. Leukemia 2009;23:1359\u201361.","journal-title":"Leukemia"}],"container-title":["Methods in Molecular Biology","Cancer Cytogenetics"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-61779-074-4_7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T14:39:57Z","timestamp":1605710397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-61779-074-4_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9781617790737","9781617790744"],"references-count":13,"URL":"https:\/\/doi.org\/10.1007\/978-1-61779-074-4_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2011]]}}}